Abstract Breast phyllodes tumors are rare neoplasms which present challenges for histological classification. Microscopic features are not always predictive of clinical behavior, and scarce data exist on the prognostic role of biological markers. Our study evaluated a series of 145 phyllodes tumors diagnosed at the Department of Pathology, Singapore General Hospital between 2006 and 2009, incorporating 91 (62.8%) benign, 40 (27.6%) borderline, and 14 (9.7%) malignant phyllodes tumors. Antibodies to keratin 15 (KRT15), transcobalamin I (TCN1), and homeobox gene Hox-B13 (HOXB13) were applied to sections cut from tissue microarray blocks. KRT15 and TCN1 positivity was defined when there was reactivity of 1% or more stromal cells, while HOXB13 positivity was defined using a H-score of 100 and above. Positive immunohistochemical expression for KRT15, TCN1, and HOXB13 was seen in 21 (14.5%), 96 (66.2%), and 66 (45.5%) of tumors, respectively. Stromal expression of KRT15, TCN1, and HOXB13 was significantly correlated with tumor grade (P \ 0.001, P \ 0.001, P = 0.012), stromal hypercellularity (P = 0.005, P \ 0.001, P = 0.023), mitotic activity (P \ 0.001), and microscopic borders (P = 0.006, P \ 0.001, P = 0.011). Co-expression of TCN1 and HOXB13 was seen in 21 of 91 (23.1%) benign, 18 of 40 (45.0%) borderline, and 11 of 14 (78.6%) malignant tumors, suggesting that the dual-marker panels of TCN1 and HOXB13 might be helpful in classifying borderline and malignant tumors. Although expression of TCN1 alone was present in all malignant and 34 of 40 (85.0%) borderline tumors, a combined panel with HOXB13 excluded some benign cases and was a better discriminant for a significant proportion of borderline and malignant tumors.
Introduction
Phyllodes tumors of the breast are uncommon fibroepithelial neoplasms that comprise 0.5 to 1.0% of all breast tumors [1, 2] . Although typically characterized by prominent leaf-like fronds, phyllodes tumors may exhibit histological features similar to the more common benign fibroadenomas. Several studies have been conducted to identify histological and biological markers that are associated with phyllodes tumors or which are predictive of malignancy [3] [4] [5] [6] [7] [8] .
In this study, we determined the immunohistochemical expression of keratin 15 (KRT15), transcobalamin I (TCN1), and homeobox gene Hox-B13 (HOXB13) in the stromal component of phyllodes tumors across all the three grades. KRT15 is a type I keratin lacking a defined type II partner and is primarily expressed in basal keratinocytes of stratified epithelium [9] . KRT15 is important for maintaining cytoplasmic stability, and several studies have reported its expression in different carcinomas [10] [11] [12] [13] . TCN1 is a vitamin B12 (cobalamin)-binding protein that carries cobalamin as it passes through the stomach and releases it in the gut where it is subsequently bound by intrinsic factor (IF) [14] . Upregulation of TCN1 in other tumors and carcinoma-associated fibroblastic differentiation of human bone-marrow-derived mesenchymal stem cells (hMSCs) has previously been studied [15, 16] . HOXB13 gene encodes transcriptional regulators responsible for development, particularly during embryogenesis [17, 18] . The gene is expressed at high levels in normal prostate tissue, with a similar or higher expression seen in prostate cancers [19] . HOXB13 immunoexpression in phyllodes tumors has revealed upregulation of HOXB13 protein in malignant relative to borderline tumors with correlations to stromal hypercellularity and atypia [20] . These proteins were selected for interrogation based on our previous findings of their corresponding genes being significantly and differentially regulated in different grades of phyllodes tumors [20] .
To the best of our knowledge, there have been no studies on KRT15 and TCN1 in phyllodes tumors. HOXB13 expression in breast cancer and its role as a predictive marker for benefit from tamoxifen treatment have previously been studied, while its expression in phyllodes tumors was investigated by our group in a small sample of formalin-fixed, paraffin-embedded tissues [17, 20] . The aim of this study is to evaluate the immunohistochemical expression of novel markers, KRT15, TCN1, and HOXB13, which may be used as adjunctive factors in classifying phyllodes tumors.
Materials and methods

Patients and tumors
This study comprised 145 cases of phyllodes tumors of the breast diagnosed at the Department of Pathology, Singapore General Hospital between 2006 and 2009. Classification into benign, borderline, and malignant grades focused on the degree of stromal hypercellularity, stromal cell atypia, stromal overgrowth, mitotic count, and nature of the microscopic borders as previously described [7, 8] . In brief, stromal hypercellularity and stromal cell atypia were categorized as mild, moderate, or marked. Stromal overgrowth, recorded as absent or present, was defined using a low-power field (49 microscope objective and 109 eyepiece, 22.902 mm 2 ) with its presence denoting stroma without epithelial elements. Stromal mitotic activity was quantified per 10 high-power fields (hpf) of the microscope objective (409 objective and 109 eyepiece, 19.64 mm 2 ) over the most mitotically active stromal areas. Borders were categorized as circumscribed or permeative. A circumscribed border was defined by a pushing margin protruding against surrounding breast tissue, while a permeative border exhibited infiltrative branches into neighboring tissue. A benign phyllodes tumor was characterized by mild or moderate stromal hypercellularity and stromal cell atypia, no stromal overgrowth, mitotic activity up to four mitoses per 10 hpf, and pushing margins. A malignant tumor was defined by marked stromal hypercellularity and stromal cell atypia, stromal overgrowth, brisk mitotic activity (C10 per 10 hpf), and infiltrative margins; the presence of a malignant heterologous element allowed for the classification of a tumor as malignant. Borderline phyllodes tumors exhibited some but not all characteristics of malignant tumors [7] .
Tissue microarray construction
Hematoxylin and eosin (H&E) sections for each of the 145 phyllodes tumors were retrieved and reviewed. Areas exhibiting a high density of stromal cells were identified and indicated using a marker on the slide. The corresponding areas were circled on the donor paraffin block and punched using the 2-mm punch on a Beecher arrayer. Three cores per case were created for 142 out of 145 tumors; whole sections were cut for three core biopsies with limited tissue. A grid of the microarray layout was made using Microsoft Excel.
Immunohistochemistry
The sections (4 lm) were cut from tissue microarray blocks and fished onto coated slides (POLYSINE, Menzelglaser). The slides were incubated overnight at 55°C to ensure tight adhesion of the sections to the slides. Deparaffinization in xylene and graded alcohol preceded antigen retrieval. For TCN1 and HOXB13, antigen retrieval was carried out by pressurized heating in the Milestone T/T Mega microwave for 15 min at 98°C in Tris-EDTA buffer (pH 9.0). KRT15 antigen retrieval was performed in the same manner using citrate buffer (pH 6.0). For all sections, endogenous peroxidase activity was blocked using 3% H 2 O 2 for 10 min. The antibodies to KRT15 (EPR1614Y, ab52816, 1:50 dilution), and TCN1 (chicken anti-TCN1, ab14273, 1:200 dilution) were applied and incubated at room temperature for 30 min, while that to HOXB13 antibody (F-9, sc-28333, 1:20 dilution) was incubated for 1 h ( [21] . The triplicate cores for cases constructed on tissue microarrays were assessed independently, and the core which yielded the highest score was used for analysis. KRT15 and TCN1 were considered positive when 1% or more of stromal cells were stained [22] , while HOXB13 positivity was defined as a H-score of 100 and above [21] .
Microarray data
The microarray data analyzed consisted of 21 phyllodes samples-six benign, 10 borderline, and five malignant derived from the data of our previous study [20] , and 93 invasive breast cancers. Microarray data were generated using HG-U133 plus 2 arrays (Affymetrix Inc). All analyses were carried out using R/BioConductor (ver. 2.12.2/ ver. 2.7). Quality control metrics were generated for all the samples using the simpleaffy [23] package (summarized in Table 2 ) and fell within acceptable ranges. CEL files were RMA normalized using the affy [24] package, and comparative statistics were generated using limma [25] .
Statistical analysis
Findings were analyzed using the SPSS software for Windows, Version 18. Clinicopathological features were correlated with KRT15, TCN1, and HOXB13 positive immunohistochemical expression using the v 2 and Fischer's exact tests. A P value of \0.05 was considered a significant result.
Results
The study group consisted of 91 (62.8%) benign, 40 (27.6%) borderline, and 14 (9.7%) malignant phyllodes tumors. Patients were women with an age range from 15 to 79 years (mean 45 years). Ethnic distribution consisted of Chinese (89; 61.4%), Malay (31; 21.4%), Indian (11; 7.6%), and others (14; 9.7%). Tumor size ranged from 10 to 250 mm (mean 58 mm; median 40 mm). The clinicopathological features of 145 phyllodes tumors stratified according to histological grade are shown in Table 3 . Three malignant tumors exhibited stromal metaplastic components of liposarcoma, chondrosarcoma, and chondro-and osteosarcoma, respectively. KRT15, TCN1, and HOXB13 positive immunohistochemical expression was seen in 21 (14.5%), 96 (66.2%), and 66 (45.5%) tumors, respectively (Table 4) . Table 5 shows the correlations of protein immunoexpression with clinicopathological features of phyllodes tumors.
KRT15 nuclear staining of weak intensity was observed; no tumors exhibited staining of moderate or marked intensity. No cytoplasmic staining was seen in any case. Borderline and malignant tumors were more likely to exhibit staining ranging from 1 to 10% of stromal cells (Fig. 1) . KRT15 immunoexpression correlated significantly with tumor grade (P \ 0.001), stromal hypercellularity (P = 0.005), stromal cell atypia (P = 0.012), mitotic activity (P \ 0.001), microscopic borders (P = 0.006), and microscopic hemorrhage (P = 0.008).
TCN1 cytoplasmic staining ranging from 1 to 80% of the stromal component was observed. Staining of weak intensity was predominant across all tumor grades, but moderate and marked staining occurred more frequently in borderline and malignant cases (Fig. 2) . TCN1 immunoexpression correlated significantly with tumor grade (P \ 0.001), stromal hypercellularity (P \ 0.001), stromal cell atypia (P \ 0.001), stromal overgrowth (P = 0.003), mitotic activity (P \ 0.001), microscopic borders (P = 0.001), and microscopic hemorrhage (P \ 0.001). HOXB13-positive H-scores ranged from 100 to 255 (Fig. 3) . HOXB13 immunopositivity correlated significantly with tumor grade (P = 0.012), stromal hypercellularity (P = 0.023), mitotic activity (P \ 0.001), microscopic borders (P = 0.011), microscopic hemorrhage (P = 0.013), and necrosis (P = 0.015).
KRT15 and TCN1 immunoreactivities were significantly correlated (P \ 0.001) as 21 out of 21 KRT15-positive tumors were also positive for TCN1. TCN1 immunoexpression correlated with HOXB13 expression (P = 0.026) with 50 out of 66 HOXB13-positive tumors also exhibiting TCN1 positivity. No significant correlation was found between KRT15 and HOXB13 status. Table 6 summarizes the relationship of biomarkers (single, double panel, and tri-panel) with different grades of phyllodes tumor in the series. TCN1 was the most sensitive marker for malignant phyllodes tumor (14/14, 100.0%, P \ 0.001), while a double panel of HOXB13 and TCN1 can categorize borderline (18/40, 45.0%) and malignant tumors (11/14, 78.6%), P \ 0.001.
Expression levels for KRT15, TCN1, and HOXB13 were compared in benign and borderline phyllodes tumors versus malignant ones. Each was found to be significantly differentially expressed. KRT15 and TCN1 were downregulated with log 2-fold changes of -5.00 (P value 2.51e-07) and -3.58 (P value 1.82e-05), respectively. Conversely, HOXB13 was upregulated with a log 2-fold change of 1.23 (P value-2.95e-05). Expression profiling data for invasive breast carcinoma samples mirrored those of malignant phyllodes tumors (Fig. 4) .
Discussion
The KRT15 gene has been shown to be underexpressed in clinical stage III breast cancers compared to normal tissue [26] . KRT15 expression in luminal progenitor cells as well as malignant breast carcinomas has also been explored [10, 11] . Franzén et al. [11] observed higher levels of KRT15 in fibroadenomas compared with carcinomas. In humans, KRT15 gene expression is upregulated when both alleles for CK14 are inactivated, and a previous study by Dunne et al. [27] revealed that the stromal component of phyllodes tumors was negative for CK14. The 21 phyllodes tumors in our study, which stained positively for KRT15 protein included four benign, 12 borderline, and five malignant cases. Although KRT15 immunoexpression was correlated with higher tumor grades, low frequency within each grade as well as weak staining intensity renders its true significance difficult to interpret. TCN1, also known as haptocorrin and vitamin B12 R binder, is a transport protein that binds vitamin B12 (cobalamin). Vitamin B12 plays important roles in nervous system functioning, hematopoeisis, and cell metabolism. Waibel et al. [14] proposed the use of synthetic cobalamin analog tailored specifically to bind to TCN1 as a method of delivering vitamin-conjugated compounds to cancer tissues. In addition, Mishra et al. [16] observed that human bone-marrow-derived mesenchymal stem cells grown in tumor-conditioned medium exhibited an upregulation of TCN1 and other carcinoma-associated fibroblast (CAF)-associated genes. While TCN1 was the most frequently In contrast to our findings using expression profiling where we found gene upregulation of KRT15 in borderline as compared with malignant phyllodes tumors, protein immunohistochemistry for KRT15 showed increasing frequency in higher-tumor grades in this current investigation [20] . Similarly, TCN1 was upregulated in benign relative to malignant tumors in our previous study, but protein expression for TCN1 was enhanced with higher-tumor grades using our tissue microarrays [20] . Several reasons exist for these seemingly discordant findings. In expression-profiling data that utilized fresh tissue, epithelial elements may have been included in the material profiled, and hence a consequent decrease in KRT15 expression was seen in malignant versus borderline tumors due to stromal overgrowth in the former. The observation of nuclear KRT15 immunostaining of stromal cells in our study is also unusual, since ordinarily, keratin expression is localized within cell cytoplasm. Translocation of expression to stromal nuclei may be related to neoplastic progression. As for TCN1, there is a dearth of data regarding its role in breast tumors, apart from a historical descriptive report of its expression in fibroadenomas and phyllodes tumors [28] . Interestingly, microarray profiling data for invasive breast carcinomas align with those of malignant phyllodes tumors, suggesting possible similarities in the expression of these markers.
The HOXB13 gene is a member of the homeobox gene family that encodes transcriptional regulators involved in cell growth and development. HOXB13 has been shown to be overexpressed in breast cancer and has also been investigated as a prognostic predictor for tamoxifen treatment in women with hormone receptor-positive breast cancer [17, 18, 29] . In a previous study by Ang et al. [20] HOXB13 gene expression was observed to be upregulated in malignant phyllodes tumors compared with borderline and benign grades, and immunohistochemistry revealed HOXB13-positive staining in two borderline and one malignant tumors, with significant correlations between immunoreactive score (H-score) and histological features All P values statistically significant of stromal hypercellularity and stromal cell atypia. In our study, 11 of 14 (78.6%) malignant tumors showed positive HOXB13 immunoexpression, corroborating the previous observation of upregulation in malignant cases. Although there was no significant correlation between HOXB13 expression and stromal atypia, our study group incorporated a larger series of tumors than that of Ang et al. and showed statistically significant correlations with stromal hypercellularity, overgrowth, mitotic activity, and microscopic borders. In our study, KRT15, TCN1, and HOXB13 immunohistochemical expression was significantly correlated with phyllodes tumor grade as well as various histological features. Individually, TCN1 was the marker most predictive of malignancy with 14 of 14 (100%) malignant tumors exhibiting stromal staining for TCN1. In benign and borderline tumors, TCN1 was expressed in 48 of 91 (52.7%) and 34 of 40 (85.0%) cases, respectively, whereas HOXB13 positivity was observed in 36 of 91 (39.6%) benign and 19 of 40 (47.5%) borderline tumors. When TCN1 and HOXB13 co-expression was assessed, 21 of 91 (23.1%) benign, 18 of 40 (45.0%) borderline, and 11 of 14 (78.6%) malignant tumors expressed both markers. While HOXB13 alone stained positively in 11 of 14 (78.6%) malignant tumors, the two-marker panels of TCN1 and HOXB13 were expressed in fewer benign and borderline tumors. Thus, the combination of TCN1 and HOXB13 coexpression represents a more reliable correlation with malignant tumors than each individual marker.
Phyllodes tumors are breast fibroepithelial neoplasms in which the stromal component is traditionally considered the neoplastic element. Previous studies have examined immunoexpression of various biological markers, such as CD34 and Ki67, and demonstrated correlations of others, such as p16, p53, pRb, and CD117, with tumor grade or recurrent disease [3] [4] [5] [6] . While many of the aforementioned markers are associated with tumor suppression or cell proliferation, there is no standardized set of biological markers, which can be used for categorizing phyllodes tumors. Most studies utilize histological parameters of stromal hypercellularity, stromal cell atypia, stromal overgrowth, mitotic activity, and microscopic borders to categorize phyllodes tumors, but each study proposes that a different set of markers is associated with increasing phyllodes tumor grade. Owing to the small sample size of most studies, immunohistochemical findings must be viewed in conjunction with histological features. In order to establish a gold standard for classifying phyllodes tumors, immunoexpression must be correlated at the molecular level. The use of tissue microarrays in our study facilitates validation of results of gene expression profiling in a larger series of cases. Currently, data regarding recurrent disease in our study are limited due to the time frame over which cases were selected for the study; only four patients in the study group experienced recurrences since the date of initial diagnosis.
Conclusion
TCN1 and HOXB13 immunoexpression in stromal cells of phyllodes tumors are significantly correlated with tumor grade and histological features, such as stromal hypercellularity, mitotic count, and microscopic borders. Coexpression of TCN1 and HOXB13 may be used to categorize borderline and malignant phyllodes tumors. Although both markers may be observed in benign tumors, concurrent expression occurs in a smaller percentage of such cases compared with borderline and malignant ones. Thus, a two-marker panel of TCN1 and HOXB13 represents a sensitive biological indicator of borderline and malignant phyllodes tumors, and further molecular studies may confirm the specificity of these markers in classifying phyllodes tumors biologically.
